clinical trial · NCT05580250
A Study of LY3526318 in Healthy Male Japanese Participants
Eli Lilly and Company·phase1·withdrawn
HealthyLY3526318PlaceboIohexolSimvastatinMetformin
brief summary
This is a study of LY3526318 in healthy male Japanese. The main purposes of this study are to: * Assess how safe and well tolerated LY3526318 is when given by mouth. * Measure how LY3526318 affects the kidney and the liver. The study will be conducted in three parts (Part A, Part B, Part C). Participants may only enroll in one part. After screening, the study will last from one to two weeks, depending on part.
started
Nov 1, 2022
primary completion
Dec 1, 2022
completion
Dec 1, 2022
last updated
Sep 8, 2026
official title
A Phase I, Single-Centre Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses of LY3526318, and to Investigate the Effect of LY3526318 on Metformin and Simvastatin Pharmacokinetics in Healthy Male Japanese Participants
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol